Overview of Drilyna

Property	Description
Active Ingredient	Choline Theophyllinate (Oxtriphylline)
Forms	Tablets, Oral Solution, Solution for Nebulization
Pharmacological Class	Bronchodilator / Xanthine Derivative
General Purpose	Relaxing the air passages in the lungs
Origin	Synthetic Choline Salt

1. What Type of Medicine is Drilyna (Choline Theophyllinate)?

Drilyna is the trade name for the pharmaceutical compound Choline Theophyllinate, which is also known by the synonym Oxtriphylline. This compound is officially classified as a Bronchodilator, belonging to the Xanthine Derivative pharmacological group. This class of medicine is primarily intended to manage the narrowing of air passages within the lungs, a condition commonly referred to as reversible bronchoconstriction. The use of xanthine derivatives for improving respiratory capacity is a clinically recognized application.

2. Composition and Origin: Is Choline Theophyllinate Synthetic?

The core active component in Drilyna is Theophylline, which is chemically linked to a choline molecule to form the specific salt, Choline Theophyllinate. While the base molecule is related to naturally occurring compounds, the finished drug substance is prepared synthetically as a choline salt to ensure purity and chemical stability. This salt structure is engineered to improve the drug’s solubility and overall gastrointestinal tolerability compared to the parent drug. Choline Theophyllinate is typically formulated as a single-ingredient product in various high-level dosage forms, including oral tablets and aqueous solutions, for administration via the oral or inhalation route, providing flexibility for different patient groups.

3. How Does Drilyna Generally Help with Breathing?

The general benefit of Choline Theophyllinate is the stabilization and widening of the airways, leading to relief of airway constriction. This therapeutic action involves a dual-action mechanism where the drug causes the smooth muscles surrounding the bronchial tubes to relax, which is the physiological definition of bronchodilation. By acting in this manner, it helps reduce the underlying tension and block triggers that cause spasms, ultimately making it generally easier for the patient to achieve and maintain better airflow. For example, individuals experiencing a sustained feeling of tightness in the chest due to airway narrowing can benefit from this medication's ability to promote smooth muscle relaxation.

What side effects are possible with Drilyna?

The safety profile of Drilyna (Choline Theophyllinate) is formally documented as being highly dependent on the serum concentration of its active component, theophylline. The frequency and severity of adverse reactions are officially noted to increase significantly when circulating levels exceed 20 mu g/mL.

Adverse Reaction Scope

Classification	Examples of Officially Listed Effects
Common/Frequent	Nausea, vomiting, headache, insomnia (difficulty sleeping), and tremors
System-Organ Classes	Gastrointestinal Disorders, Nervous System Disorders, and Cardiac Disorders
Serious Adverse Reactions	Seizures (convulsions), Ventricular Arrhythmias (irregular heartbeats), and Cardiac Arrest

The most severe reactions are associated with toxicity and may occur without prior signs of less serious effects. Less serious signs, such as nausea and restlessness, are noted as potentially transient upon the start of therapy.

Population-Specific Safety Considerations

Official regulatory documents identify specific groups where theophylline clearance is reduced by 30% to 50% or more, leading to an increased risk of toxicity. These populations include older adults (over 60 years), patients with hepatic impairment (e.g., cirrhosis), and patients with congestive heart failure. Reduced clearance is also documented in neonates and during the third trimester of pregnancy.

Safety-Related Restrictions

The fundamental regulatory restriction is the concentration-dependent toxicity. Due to this risk profile, official labeling specifies that the serum concentration of theophylline must be measured frequently in acutely ill patients and periodically in patients receiving long-term therapy to manage risk.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

This section outlines the officially documented clinical manifestations and required emergency actions for an overdose of Drilyna (Choline Theophyllinate), as stated in government regulatory sources.

Overdose may initially present with gastrointestinal symptoms such as severe nausea, vomiting, abdominal pain, or diarrhea. CNS manifestations are also officially documented, including headache, tremor, restlessness, confusion, and a change in behavior.

When to Seek Immediate Medical Attention

Official prescribing information requires patients to seek immediate medical attention and stop taking the medication if they experience any of the following acute symptoms:

Seizures (convulsions)
Increased or irregular heartbeats (cardiac arrhythmias)
Severe or persistent nausea and vomiting

Severe Outcomes and Monitoring

Regulatory documents highlight that overdose can lead to severe outcomes, including life-threatening ventricular arrhythmias, peripheral vascular collapse, permanent neurologic deficits, and the possibility of death. No specific antidote is listed in the official labeling.

For any suspected overdose, the serum theophylline concentration measurement is cited as the only reliable method for predicting potentially life-threatening toxicity and must be obtained and analyzed immediately.

Population-Specific Risk

Regulatory documents explicitly state that the risk of severe toxicity is increased in certain populations, including the elderly and those with co-existing conditions such as hepatic impairment or severe cardiovascular disease.

Therapeutic Uses of Drilyna

What Drilyna Treats: Main Uses and Benefits

Drilyna may be part of symptomatic management in domains where additional symptomatic support is appropriate to help manage acute, distressing manifestations. Its primary role is to provide support that helps ease the overall symptom burden, and supports general well-being during symptomatic phases.

The medication is considered relevant for easing acute symptom intensity, addressing challenging symptom clusters, and assisting with maintaining functional stability during episodes of disruption. It helps address symptom clusters that may appear suddenly or intensify over time, making it applicable within clinical settings that involve acute or disruptive symptom patterns. Drilyna is considered relevant in conditions marked by increased physiological stress, such as those characterized by episodic or fluctuating manifestations.

“The use of this medication is relevant for easing discomfort and tension during periods of increased symptomatic load.”

Quick Fact: Relevant for managing symptoms that interfere with daily comfort

Drilyna is commonly used when symptoms intensify, providing temporary assistance in symptom stabilization which may assist with maintaining functional stability when symptoms are more noticeable. It is relevant in contexts where additional symptomatic support is appropriate, particularly when symptoms create noticeable interference with daily comfort or routine activities.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Drilyna (Choline Theophyllinate)

Drilyna eligibility is strictly defined by regulatory documents, which establish three key usage statuses. Use is contraindicated for any patient with a documented hypersensitivity to xanthine derivatives, an uncontrolled seizure disorder, or specific coronary artery disease where cardiac stimulation is a risk.

Age-Related Eligibility	Condition-Specific Restrictions
Conditional Use applies to older adults (over 60) and infants (under 1 year) due to documented reduced drug clearance.
Use is restricted in patients with impaired hepatic function, cardiac failure, sepsis, or sustained high fever, as these conditions reduce drug clearance.

Eligibility is also conditional for pregnancy (US FDA Category C) and lactation, as the active component is excreted into human milk, requiring infant monitoring. Use requires caution in patients with severe hypertension or a history of peptic ulcer disease.

Official regulatory documents define the overall eligibility profile by identifying absolute prohibitions and specific conditional use scenarios tied to age and disease states that alter drug clearance, ensuring usage is restricted to established population parameters.

What should I know about interactions with other medicines?

Drilyna Interactions with other medicines and products

The official regulatory profile for Drilyna (Choline Theophyllinate) details several clinically significant interaction patterns, primarily centered on alterations to the drug's systemic clearance and pharmacodynamic effects.

Formally Restricted Combinations

Regulatory authorities officially state that co-administration with specific medicinal products, such as Riociguat and Viloxazine, is not recommended.

Pharmacokinetic Clearance Modification

Clearance of the active component, Theophylline, is largely mediated by the Cytochrome P-450 1A2 (CYP1A2) enzyme. Co-administration with inhibitors, including the antimicrobials Ciprofloxacin and Erythromycin, can substantially decrease clearance, leading to accumulation. Conversely, CYP inducers like Rifampin enhance clearance, which can reduce the systemic exposure of theophylline.

Pharmacodynamic Interactions

Co-administration with beta2-agonists is documented to increase the risk of enhanced adverse effects, specifically hypokalemia. Additionally, the medicine is officially noted to be an adenosine receptor antagonist and may interfere with diagnostic agents like Regadenoson, requiring avoidance for a minimum of 12 hours prior to administration.

Non-Drug and Population Factors

Substances such as tobacco smoking and consumption of charbroiled beef are officially documented to enhance clearance. The risk of accumulation is officially heightened in elderly patients and individuals with hepatic impairment due to reduced clearance, as noted in the product labeling.

Mechanism of Action

How Drilyna Works

The active moiety of Drilyna, Theophylline, engages in a multi-modal pharmacodynamic profile focused on modulating key respiratory pathways. Its primary mechanism is the non-selective inhibition of Phosphodiesterases (PDE), specifically PDE3 and PDE4 isozymes. By blocking these enzymes, Theophylline prevents the breakdown of the signaling molecule cyclic AMP ( cAMP) in smooth muscle cells, initiating an intracellular cascade that results in the relaxation of bronchial smooth muscle.

Simultaneously, Theophylline acts as a non-selective antagonist of Adenosine Receptors. Blocking these receptors inhibits the functional effects of adenosine on cellular structures, thereby decreasing the influence of mediators associated with smooth muscle contraction. A third domain involves contributing to the restoration of activity of Histone Deacetylase 2 ( HDAC2). This action on gene transcription influences the expression of pro-inflammatory proteins, which contributes to an alteration in the long-term physiological responsiveness of the airways.

Dosage and Administration Information

General Administration Guidelines for Drilyna (Choline Theophyllinate)

Drilyna is a trade name for Choline Theophyllinate, which functions as a Bronchodilator. The protocols for its use are structured to manage its narrow therapeutic index (NTI).

Parameter	Instruction Details
Route of Administration	The medicine is approved for the oral route (tablets, solution) for chronic maintenance, and the intravenous (IV) route for acute clinical settings.
Dosing Schedule	Dosing is individualized based on patient factors and adjusted to maintain a peak serum Theophylline concentration between 10 and 15 micrograms/mL. Initial dose changes should be made in small increments, typically 10% to 25% of the daily dose, and no more often than every three days to ensure steady state is reached.
Frequency Pattern	Extended-release oral forms are typically administered once or twice daily (e.g., every 12 hours or every 24 hours), while immediate-release forms may be given every 6 to 8 hours.
Administration Constraints	Extended-release tablets must be swallowed whole and should not be crushed or chewed, as this can lead to rapid release. IV solutions must not be admixed with other drugs.
Population Adjustments	Doses should be calculated based on lean (ideal) body weight. Older adults and patients with conditions that impair clearance (e.g., cardiac failure) typically require lower doses and careful monitoring.
Missed Dose Rule	If a dose is missed, the patient should take the next scheduled dose at the normal time and not double the dose.

The administration of Drilyna is a precisely managed procedure governed by the need for Therapeutic Drug Monitoring (TDM). This monitoring ensures that the amount of medicine in the blood remains within the specified therapeutic range, which dictates how the dose is started, titrated, and maintained over time. Clinical practice emphasizes adherence to strict time intervals and proper handling of the dosage form to guarantee a controlled and consistent drug release.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Drilyna (Choline Theophyllinate)

The research on Drilyna, known as Choline Theophyllinate, largely focuses on its class of medicine, the xanthine derivatives, which are studied in the context of bronchodilation. The evidence primarily comes from controlled studies and analyses that research the relationship between the medicine and breathing function and related symptoms in conditions where air passages narrow.

Evidence Overview for Chronic Airflow Limitation

The evidence for this medicine in conditions marked by chronic narrowing of the air passages, such as asthma and chronic obstructive pulmonary disease (COPD), was evaluated in Randomized Controlled Trials (RCTs) and systematic reviews. The studies examined objective measurements of lung function, such as the Forced Expiratory Volume in 1 second ( FEV1), to observe how they were related to the medication, as well as patient-reported outcomes describing perceived discomfort. Studies reported data show patterns related to FEV1 measurements taken during the study period. However, research highlights that findings for certain outcomes, particularly those reflecting subjective symptom scores and overall quality of life, were mixed or inconsistent across different trials. Comparative evidence is lacking against other classes of treatment.

Research on Reversible Airways Obstruction and Acute Effects

Research exploring the relationship between Drilyna and reversible airway narrowing often uses short-term, single-dose studies, including double-blind crossover trials. These studies primarily focused on research examining temporary physiological imbalance. The findings indicate patterns was observed in spirometric values following administration. The evidence contributes to understanding the short-term physiological reaction associated with the drug's administration. What remains uncertain is the full scope of the relationship was observed in over a very long duration, and the research often relies on surrogate markers (like FEV1 measurements) rather than extended data on functional stability in a patient’s daily life.

Key Evidence Gaps and Areas of Uncertainty

The body of research, particularly for older drugs in this class, presents several areas of uncertainty. Evidence quality varies across studies, and many of the key trials were conducted decades ago, meaning comparative evidence is lacking against the most modern standard-of-care inhalers. Research protocols studies monitored the active substance in the blood within defined ranges. Finally, long-term evidence focusing purely on patient-reported outcomes describing perceived discomfort and functional independence, rather than just objective lung measurements, is not fully established.

Frequently Asked Questions (FAQ)

Common questions about Drilyna (FAQ)

Q: Does Drilyna have a long-term effect or only when I'm taking it?

A: The active component in Drilyna works as a bronchodilator to widen air passages while the medication is active in the body. Beyond that, official information states it also influences key enzymes, which contributes to altering the long-term physiological responsiveness of the airways during chronic maintenance use.

Q: What kind of foods or drinks should I avoid while taking Drilyna?

A: Official instructions advise caution or avoidance of certain substances that can affect drug levels in your body. This includes smoking tobacco or cannabis, eating charbroiled beef, and consuming large amounts of caffeine from food or beverages. Official instructions mention that alcohol consumption may need to be limited or avoided.

Q: Can teenagers or children use Drilyna?

A: The active component is generally used for children, and regulatory information includes dosing details for children over the age of 12. However, children under 1 year of age are identified as a population that requires specific caution and dose adjustment due to a higher risk of side effects.

Q: How long were the research studies on Drilyna?

A: Studies on this medication range from short-term trials, where only a single dose is given, to longer-term studies. The longer-term evidence supports the drug's use for the chronic maintenance therapy of certain respiratory conditions.

Q: What should I do if I think I'm having a serious reaction to Drilyna?

A: Official regulatory text indicates that if signs or symptoms consistent with toxicity occur (such as persistent vomiting, seizures, or irregular heartbeats), subsequent doses are often withheld and the drug's concentration in the blood is measured.

Q: What is the longest period of time people have taken Drilyna in studies?

A: Clinical data supports the medicine's use for chronic maintenance therapy for respiratory conditions. The length of specific clinical trials varies, focusing on both short-term physiological effects and the long-term management of symptoms.

Q: Are there any specific lifestyle changes recommended while on Drilyna?

A: Official labeling documents that smoking tobacco or cannabis can affect the drug’s levels in the body, which is important to monitor. Additionally, official labeling states that consumption of alcohol and large amounts of caffeine may need to be limited or avoided.

Q: How quickly does Drilyna start to work after I take it?

A: The onset of the drug’s action is directly related to the time it takes for the active component to reach therapeutic blood levels. This time differs depending on whether the immediate-release or the extended-release dosage form is used.

Q: Is Drilyna a controlled substance?

A: The medication is classified as a prescription-only drug. Regulatory scheduling lists confirm that Drilyna is not classified as a federally controlled substance.

Q: Can I take Drilyna if I'm already taking an antidepressant?

A: Official drug interaction tables indicate that antidepressant medications are known to interact with the active component of Drilyna. This interaction may potentially increase the drug's concentration in the body, which can lead to a higher risk of side effects.

Q: Is it safe to drink alcohol while on Drilyna?

A: Official regulatory instructions state that the consumption of alcohol may need to be avoided or limited while taking this medication.

Q: Do you need a special kind of prescription to get Drilyna?

A: Drilyna is officially classified as a prescription-only medicine. This means it requires a prescription from a licensed healthcare professional, but it does not generally require a special type of prescription beyond what is standard for prescribed medicines.

Q: Is Drilyna available as a generic medicine?

A: Yes, the active component of Drilyna, Theophylline, is widely available as a generic medicine. This includes various dosage forms as documented in regulatory listings like DailyMed.

Q: Does taking Drilyna affect your ability to drive or operate machinery?

A: The drug is associated with nervous system side effects such as dizziness, nervousness, and restlessness. Official warnings are provided regarding operating machinery or driving due to the association with nervous system side effects.

Q: Is there a warning about stopping Drilyna suddenly?

A: Yes, the official label includes a warning regarding discontinuation. Abruptly stopping the medicine, especially after long-term use, may lead to the return or worsening of the respiratory symptoms the drug is intended to manage.

Q: Does Drilyna interact with herbal supplements like St. John's Wort?

A: Official drug interaction tables document that co-administration with the herbal supplement St. John's Wort may cause an interaction. This interaction could potentially lower the drug's levels in the body, thereby making it less effective.

Q: Is Drilyna safe for someone with kidney issues?

A: The active component is primarily removed from the body by the kidneys. Regulatory documents indicate that patients with impaired kidney function typically require dosage adjustments and close monitoring of blood levels due to the risk of drug accumulation.

Q: What are the ingredients in Drilyna, besides the main active component?

A: The official labeling lists the active component along with various inactive ingredients, often referred to as excipients. These can include compounds like lactose, magnesium stearate, and various cellulose derivatives used in the formulation of the product.

Q: Does Drilyna affect mood or energy levels?

A: Official adverse reaction reports document that the drug's active component has stimulant effects on the central nervous system (CNS). Side effects related to mood and energy include nervousness, irritability, and restlessness.

Q: Are there specific times of day that are best for taking Drilyna?

A: The recommended time of administration depends on the specific dosage form. For example, some extended-release forms are typically taken once daily, often in the morning, or divided twice daily to maintain stable blood levels, according to administration guidelines.

Q: Can Drilyna be taken with or without food?

A: Official patient instructions specify that taking extended-release forms with food can affect drug levels. Regulatory guidelines emphasize the importance of maintaining a consistent administration pattern, such as always taking the medicine with food or always without food.

Q: Why is Drilyna sometimes mentioned with the term 'Black Box Warning'?

A: The FDA label includes a Boxed Warning (often referred to as a Black Box Warning). This is due to the potential for serious and life-threatening side effects, such as seizures and severe irregular heartbeats, especially when blood levels of the active component are too high.

Q: Does Drilyna cause issues with memory or concentration?

A: While memory loss is not listed as a direct side effect, adverse event documentation includes nervous system-related issues like confusion, disorientation, and nervousness. These effects are particularly noted in cases of high drug levels or overdose.

Q: What is the likelihood of getting one of the less common side effects from Drilyna?

A: The frequency of all adverse effects, including less common ones, is documented in the official labeling. The likelihood is often described using specific descriptive terms, such as 'common' or 'uncommon,' and sometimes includes percentage estimates derived from clinical trial data.

Q: Does Drilyna interact with common vitamins or mineral supplements?

A: Official drug interaction information indicates that the active component may interfere with the activity of certain vitamins, such as Vitamin B6. The need for supplementation is based on clinical evaluation to help manage related side effects.

Q: Is Drilyna known to cause dependency or withdrawal issues?

A: The drug is not listed in regulatory documents as causing clinical dependency. However, abrupt discontinuation, particularly after long-term use, is noted to potentially lead to the recurrence or worsening of respiratory symptoms.

How should Drilyna be stored and disposed of?

How to Store and Dispose of Drilyna

The storage and disposal of Drilyna must strictly adhere to instructions provided in the official regulatory labeling to maintain product quality and safety.

Required Storage Conditions

Drilyna should be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be protected from light and protected from moisture. It is required that Drilyna be stored out of the reach of children and dispensed in a tight, light-resistant container.

Disposal Instructions

Unused or expired Drilyna must not be flushed down the toilet or sink. Acceptable disposal methods include utilizing an authorized drug take-back program or discarding in the household trash. When disposing in the trash, the medicine must be mixed with an undesirable substance, sealed in a bag or container, and all identifying personal information must be removed from the original label.

Drilyna